February 7, 2020
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) remained the top-selling drug in the Japanese drug sales ranking in January, racking up sales of 11.3 billion yen on an NHI price basis, according to a monthly snapshot report released by market research firm...read more